Lynch Syndrome Integrative Epidemiology and Genetics
Recruiting · NCT06582914 · Observational (researchers observe without assigning treatment) · Lead sponsor: University of Colorado, Denver
View the official record on ClinicalTrials.gov →What this trial is about
The vision of the "Lynch syndrome INtegrative Epidemiology And GEnetics" (LINEAGE) Consortium is to collaboratively improve the lives and longevity of individuals and families with Lynch syndrome. The mission of the LINEAGE Consortium is to collaboratively improve Lynch syndrome care through high-quality research. This consortium will provide intellectual and infrastructure support to facilitate development of research questions, collection of standardized data and biospecimens, support of grant applications, and generation of collaborative manuscripts. Our aims are to: I. Establish a prospective cohort of individuals with Lynch syndrome II. Collect standardized longitudinal clinical and biosample data to elucidate Lynch Syndrome epidemiology and gene-host interactions III. Promote intervention trials to improve cancer prevention and early detection in Lynch Syndrome
Who can take part
Inclusion criteria
- • Adults age over 18 years
- Eligible patients must have at least one variant of uncertain significance (VUS), pathogenic or likely pathogenic variant (PV/LPV) in MLH1, MSH2, MSH6, PMS2, or EPCAM, which will be confirmed by genetic testing results (obtained as part of routine care) and a review of the variant in ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/).
- Individuals who are an obligate carrier of a LS PV/LPV that is confirmed in the family.
Exclusion criteria
- Age under 18
Where it is running
2 locations listed across 2 US states.
- University of Colorado - Aurora, Colorado, United States
- University of Chicago - Chicago, Illinois, United States